Deucravacitinib

• Plaque Psoriasis
• Moderate to Severe Psoriasis
• Oral Psoriasis Treatment
• TYK2 Inhibitor Therapy

Deucravacitinib, sold under the brand name Sotyktu, is the first oral selective tyrosine kinase 2 (TYK2) inhibitor approved for moderate-to-severe plaque psoriasis. Unlike older oral systemic therapies for psoriasis, which were largely repurposed immunosuppressants with broad safety burdens, deucravacitinib was purpose-designed to interrupt the IL-23 / IL-17 axis at the receptor signaling level. For patients who have struggled with topicals, who do not want a self-injected biologic, or who have failed apremilast, this medication offers a meaningful new option that compares favorably with several established systemic agents in head-to-head trials.

Mechanism of Action

TYK2 is a member of the Janus kinase (JAK) family, which transduces signals from a number of cytokine receptors through STAT proteins. TYK2 specifically pairs with JAK2 to mediate signaling from IL-12 and IL-23 receptors and pairs with JAK1 to mediate type I interferon signaling. Because IL-23 is the master driver of pathogenic Th17 cells in psoriasis — and because Th17-derived IL-17 is the proximal cytokine producing keratinocyte hyperproliferation and neutrophilic plaque inflammation — blocking TYK2 effectively cuts the upstream wire to the entire psoriatic cascade.

What distinguishes deucravacitinib from older JAK inhibitors is where it binds. Drugs like tofacitinib and upadacitinib bind the catalytic ATP-binding pocket of the kinase domain, which is highly conserved across JAK1, JAK2, JAK3, and TYK2 and creates inevitable cross-reactivity. Deucravacitinib binds the regulatory pseudokinase (JH2) domain of TYK2, locking the enzyme in an autoinhibited conformation through an allosteric mechanism. Because the JH2 domain sequence diverges substantially across JAK family members, the resulting selectivity for TYK2 is roughly 100- to 2,000-fold over JAK1, JAK2, and JAK3 at therapeutic exposures. That translates clinically into a labeling that does not carry the boxed warning shared by ATP-competitive JAK inhibitors regarding serious infections, malignancy, thrombosis, and cardiovascular events — though prescribers still monitor carefully. Patients can read more about how psoriasis is approached on our dermatologic specialty page and our skin cancer screening guide for related dermatology context.

Clinical Use

Deucravacitinib is FDA-approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the pivotal POETYK PSO-1 and POETYK PSO-2 trials, roughly 53 to 58 percent of patients achieved PASI 75 at week 16, compared with about 35 percent on apremilast and 9 to 13 percent on placebo, with continued improvement out to a year. Patients who switched from apremilast to deucravacitinib at week 24 typically saw further skin clearance. Real-world placement varies by clinician and payer: some position deucravacitinib as a step before injectable biologics for patients with moderate disease who prefer pills; others reserve it for those who have failed apremilast or methotrexate. It is not yet labeled for psoriatic arthritis, although phase 2 data are encouraging and many rheumatologists watch this space closely. Patient selection favors those with predominantly cutaneous disease, those wanting an oral option, and those without significant active infection or untreated latent tuberculosis. For comparison with other systemic options, the American Academy of Dermatology psoriasis resource reviews the broader landscape and the role of biologic and oral systemic therapies.

How to Take It

The dose is fixed at one 6 mg tablet by mouth once daily, with or without food. There is no titration schedule, which makes initiation simple. Patients typically notice itch reduction within two to four weeks and visible plaque thinning by week 8, with peak response between weeks 16 and 24. Storage is at room temperature, away from moisture; tablets should be kept in the original bottle. If a dose is missed, take it as soon as remembered on the same day, then resume the normal schedule the next day — never double up. Drinking grapefruit juice does not require dose adjustment because deucravacitinib metabolism is dominated by CYP1A2 rather than CYP3A4. Smoking induces CYP1A2 and may modestly lower exposure, although no formal dose change is recommended for smokers; abrupt smoking cessation could conversely raise drug levels. Patients should not crush or split the tablet, as this has not been studied.

Monitoring and Follow-Up

Before starting, screen for active and latent tuberculosis (interferon-gamma release assay or PPD), check hepatitis B and C serologies, and obtain baseline CBC with differential, comprehensive metabolic panel, lipid panel, and creatine phosphokinase (CPK). Routine repeat labs are not mandated by the label, but most dermatologists check CBC, liver enzymes, lipids, and CPK at three months and then every six to twelve months. Triglyceride elevations, when they occur, usually appear within the first three months and respond to standard lipid-lowering measures; an LDL above 130 mg/dL or triglycerides above 500 mg/dL should prompt intervention. CPK elevations greater than five times the upper limit of normal, particularly with muscle pain or dark urine, warrant holding therapy and evaluating for rhabdomyolysis. Any new lymphadenopathy or persistent infection should trigger a clinical review. Reviewing your understanding cholesterol results on schedule keeps small drifts from becoming clinical problems.

Special Populations

In the elderly, no dose adjustment is required, although infection risk and concomitant medications warrant heightened vigilance. Renal impairment up to and including end-stage renal disease does not require dose change because deucravacitinib has minimal renal clearance, although severe disease was not well represented in trials. Mild hepatic impairment is permitted; moderate and severe hepatic impairment are not recommended pending more data. For pregnancy, animal studies have shown developmental toxicity at high exposures and human data are sparse; women of childbearing potential should use effective contraception and discuss any planned pregnancy with their dermatologist. Lactation data are absent; given the molecular weight, oral infant absorption would be expected to be low, but a benefit-risk discussion is essential. Pediatric safety and efficacy have not been established; trials in adolescents are ongoing. Patients with prior or current malignancy were excluded from pivotal trials, and use in this group should be individualized.

When to Contact Your Doctor

Call for fever, productive cough, dysuria, painful skin redness with streaking, or any infection that does not resolve in a few days, since immunomodulation can mask early warning signs. Persistent muscle pain or weakness, dark cola-colored urine, or unexplained tenderness suggests possible rhabdomyolysis and warrants prompt evaluation. New or worsening mouth ulcers that interfere with eating, recurrent shingles, or unusual cold sores deserve attention. Any chest tightness, swelling of the face or tongue, or hives after a dose suggests hypersensitivity. Patients should keep their primary care team informed because vaccination timing, especially for live vaccines such as MMR, varicella, and yellow fever, must be coordinated. The FDA Sotyktu label and MedlinePlus deucravacitinib page provide additional consumer information.

Practical Tips for Daily Use

Consistent daily timing is the single most important practical habit with deucravacitinib. Patients who anchor the dose to an existing routine — morning coffee, brushing teeth at night, or a specific meal — show better adherence and fewer missed doses. Setting a phone alarm or using a weekly pill organizer is worthwhile in the first months. Because the medication takes weeks to show full benefit, many patients become discouraged by week 4 if they expected faster results; reviewing photos of plaques every two weeks rather than checking daily helps see incremental gains that are otherwise invisible. Continue topical therapies as directed during the ramp-up period; most dermatologists taper topicals after meaningful systemic response is established. Sun-protective behaviors matter more than usual on systemic immunomodulators because of the modest skin cancer risk that accompanies prolonged immune modulation — daily sunscreen, broad-brimmed hats, and rash-guard swimwear are reasonable in the Florida climate. Annual full-body skin examinations with a dermatologist help catch any new lesions early. Finally, alcohol does not have a specific interaction with deucravacitinib but heavy alcohol use raises liver enzymes and complicates lab interpretation; moderation simplifies monitoring.

Working With Your Care Team

Deucravacitinib offers a thoughtful, targeted way to gain meaningful skin clearance without injections. Our dermatology and primary care teams coordinate baseline screening, infusion-free monitoring, and collaboration with your insurer's specialty pharmacy. Schedule a visit to discuss whether oral TYK2 inhibition fits your psoriasis treatment plan.